LXEO on Nasdaq
Lexeo Therapeutics, Inc.
We are a clinical stage genetic medicine company dedicated to reshaping heart health by applying pioneering science to fundamentally change how cardiovascular diseases are treated.3 From its latest annual report
Price unavailable
Last updated Oct 19, 2026.
Overview
Compare with Cardiff Oncology, Inc., ImageneBio, Inc. or Compass Therapeutics, Inc., or pick any stock.
- TickerLXEO on Nasdaq1
- IndustryBiological Products, (No Diagnostic Substances)1
- HeadquartersNew York, New York1
- Business address345 Park Avenue South, Floor 6, New York, Ny 100102
- Filer category, Emerging growth company2
See how the biggest companies compare on our leaderboards
We are a clinical stage genetic medicine company dedicated to reshaping heart health by applying pioneering science to fundamentally change how cardiovascular diseases are treated. We are advancing a portfolio of therapeutic candidates that take aim at the underlying genetic causes of conditions, including Friedreich ataxia, or FA, cardiomyopathy, plakophilin-2, or PKP2, arrhythmogenic cardiomyopathy, and other devastating diseases with high unmet need.3 From its latest annual report
Financials
From the company’s reports to the SEC. Every number links to the filing it came from.
Key numbers, fiscal 2022
Where the money goes
Where each dollar of revenue went, fiscal 2022
- Research and development100¢$49.2M
- Interest0¢$91.0K
Out of $654.0K in revenue.4 The company lost money this year.
Financial statements
Every line of the income statement as filed: the last 2 fiscal years, latest first.7
| Period ending | 2025-12-31 | 2024-12-31 |
|---|---|---|
| Research and development expenses | $63.8M | $74.1M |
| General and administrative | $45.5M | $31.7M |
| Total operating expenses | $109.3M | $105.8M |
| Operating loss | -$109.3M | -$105.8M |
| Gain on long-term investment | $3.4M | $0 |
| Other expense, net | -$18.0K | -$9.0K |
| Interest expense | -$95.0K | -$137.0K |
| Interest income | $6.1M | $7.6M |
| (Amortization of premium) accretion of discount on investments in U.S. Treasury securities, net | -$111.0K | $23.0K |
| Total other income and expense | $9.3M | $7.4M |
| Loss from operations before income taxes | -$100.0M | -$98.3M |
| Income taxes | $0 | $0 |
| Net loss | -$100.0M | -$98.3M |
| Net unrealized gain (loss) on investments | $291.0K | -$103.0K |
| Total other comprehensive gain (loss) | $291.0K | -$103.0K |
| Comprehensive loss | -$99.7M | -$98.4M |
| Net loss per common share, basic | -$1.86 | -$3.09 |
| Net loss per common share, diluted | -$1.86 | -$3.09 |
| Weighted average number of shares outstanding used in computation of net loss per common share, basic | 53.6M shares | 31.8M shares |
| Weighted average number of shares outstanding used in computation of net loss per common share, diluted | 53.6M shares | 31.8M shares |
No quarter-by-quarter statement was filed.
Every line of the balance sheet as filed: the last 3 fiscal years (annual) or 3 quarters (quarterly), latest first.7
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Cash and cash equivalents | $63.0M | $35.0M | |
| Current portion of investments in U.S. Treasury securities | $118.8M | $86.5M | |
| Prepaid expenses and other current assets | $6.6M | $4.6M | |
| Total current assets | $188.4M | $126.1M | |
| Non-current portion of investments in U.S. Treasury securities | $64.8M | $7.0M | |
| Long-term investment | $3.4M | $0 | |
| Restricted cash | $3.2M | $3.3M | |
| Property and equipment, net | $1.1M | $1.0M | |
| Lease right-of-use assets - finance | $1.1M | $1.5M | |
| Lease right-of-use assets - operating | $6.6M | $8.1M | |
| Total assets | $268.7M | $146.9M | |
| Accounts payable | $4.9M | $6.4M | |
| Accrued expenses and other current liabilities | $9.3M | $13.8M | |
| Current portion of lease liabilities - finance | $518.0K | $570.0K | |
| Current portion of lease liabilities - operating | $2.2M | $2.1M | |
| Total current liabilities | $16.8M | $22.8M | |
| Non-current portion of lease liabilities - finance | $327.0K | $817.0K | |
| Non-current portion of lease liabilities - operating | $4.9M | $6.4M | |
| Total liabilities | $22.0M | $30.1M | |
| Common stock, $0.0001 par value, 500,000,000 shares authorized as of December 31, 2025; 73,001,766 shares issued and 73,001,350 shares outstanding as of December 31, 2025; 500,000,000 shares authorized as of December 31, 2024; 33,079,209 shares issued and 33,071,261 shares outstanding as of December 31, 2024 | $7.0K | $3.0K | |
| Treasury stock, at cost, 3,827 common shares as of December 31, 2025 and as of December 31, 2024 | -$17.0K | -$17.0K | |
| Additional paid-in capital | $626.6M | $397.1M | |
| Accumulated other comprehensive gain (loss) | $188.0K | -$103.0K | |
| Accumulated deficit | -$380.1M | -$280.2M | |
| Total stockholders' equity | $246.7M | $116.8M | $113.5M |
| Total liabilities and stockholders' equity | $268.7M | $146.9M | |
| Common stock, par value per share | $0.00 | $0.00 | |
| Common stock, Authorized | 500.0M shares | 500.0M shares | |
| Common Stock, Shares issued | 73.0M shares | 33.1M shares | |
| Common stock, Outstanding | 73.0M shares | 33.1M shares | |
| Treasury stock, common shares | 3.8K shares | 3.8K shares |
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Cash and cash equivalents | $63.0M | $35.0M | |
| Current portion of investments in U.S. Treasury securities | $118.8M | $86.5M | |
| Prepaid expenses and other current assets | $6.6M | $4.6M | |
| Total current assets | $188.4M | $126.1M | |
| Non-current portion of investments in U.S. Treasury securities | $64.8M | $7.0M | |
| Long-term investment | $3.4M | $0 | |
| Restricted cash | $3.2M | $3.3M | |
| Property and equipment, net | $1.1M | $1.0M | |
| Lease right-of-use assets - finance | $1.1M | $1.5M | |
| Lease right-of-use assets - operating | $6.6M | $8.1M | |
| Total assets | $268.7M | $146.9M | |
| Accounts payable | $4.9M | $6.4M | |
| Accrued expenses and other current liabilities | $9.3M | $13.8M | |
| Current portion of lease liabilities - finance | $518.0K | $570.0K | |
| Current portion of lease liabilities - operating | $2.2M | $2.1M | |
| Total current liabilities | $16.8M | $22.8M | |
| Non-current portion of lease liabilities - finance | $327.0K | $817.0K | |
| Non-current portion of lease liabilities - operating | $4.9M | $6.4M | |
| Total liabilities | $22.0M | $30.1M | |
| Common stock, $0.0001 par value, 500,000,000 shares authorized as of December 31, 2025; 73,001,766 shares issued and 73,001,350 shares outstanding as of December 31, 2025; 500,000,000 shares authorized as of December 31, 2024; 33,079,209 shares issued and 33,071,261 shares outstanding as of December 31, 2024 | $7.0K | $3.0K | |
| Treasury stock, at cost, 3,827 common shares as of December 31, 2025 and as of December 31, 2024 | -$17.0K | -$17.0K | |
| Additional paid-in capital | $626.6M | $397.1M | |
| Accumulated other comprehensive gain (loss) | $188.0K | -$103.0K | |
| Accumulated deficit | -$380.1M | -$280.2M | |
| Total stockholders' equity | $246.7M | $116.8M | $113.5M |
| Total liabilities and stockholders' equity | $268.7M | $146.9M | |
| Common stock, par value per share | $0.00 | $0.00 | |
| Common stock, Authorized | 500.0M shares | 500.0M shares | |
| Common Stock, Shares issued | 73.0M shares | 33.1M shares | |
| Common stock, Outstanding | 73.0M shares | 33.1M shares | |
| Treasury stock, common shares | 3.8K shares | 3.8K shares |
Cash flow is reported year to date, not quarter by quarter, so there are no separate quarterly figures.
Every line of the cash flow as filed: the last 2 fiscal years, latest first.7
| Period ending | 2025-12-31 | 2024-12-31 |
|---|---|---|
| Net loss | -$100.0M | -$98.3M |
| Reduction in the carrying amount of ROU assets, operating | $1.5M | $1.4M |
| Reduction in the carrying amount of ROU assets, finance | $320.0K | $325.0K |
| Stock based compensation expense | $12.1M | $12.5M |
| Depreciation and amortization expense | $268.0K | $304.0K |
| Non-cash gain on long-term investment | -$3.4M | |
| Net realized gain on investments in U.S. Treasury securities | -$17.0K | |
| Amortization of premium (accretion of discount) on investments in U.S. Treasury securities | $111.0K | -$23.0K |
| Prepaid expenses and other current assets | -$2.0M | -$1.7M |
| Accounts payable | -$1.6M | $2.4M |
| Accrued expenses and other current liabilities | -$4.4M | $3.4M |
| Lease liabilities, operating | -$1.5M | -$1.3M |
| Lease liabilities, finance | -$9.0K | $10.0K |
| Net cash used in operating activities | -$98.6M | -$81.2M |
| Purchase of property and equipment | -$397.0K | -$481.0K |
| Purchases of investments | -$195.4M | -$93.6M |
| Proceeds from sales or maturities of investments | $105.5M | |
| Net cash used in investing activities | -$90.3M | -$94.1M |
| Proceeds from exercise of stock options | $59.0K | $491.0K |
| Payments on finance leases | -$533.0K | -$410.0K |
| Treasury stock repurchases | -$17.0K | |
| Proceeds from common stock issuances under 2023 ESPP | $270.0K | |
| Proceeds from issuance of common stock upon private placement offering, net of commissions and offering costs | $95.0M | |
| Proceeds from issuance of common stock, pre-funded warrants and warrants to purchase common stock upon May 2025 Private Placement | $80.0M | |
| Proceeds from issuance of common stock and pre-funded warrants to purchase common stock upon October 2025 Financing Transactions | $153.8M | |
| Third-party commissions and offering costs incurred upon October 2025 Financing Transactions | -$9.8M | |
| Net cash provided by financing activities | $216.8M | $88.8M |
| Net change in cash, cash equivalents and restricted cash | $28.0M | -$86.5M |
| Interest paid | $104.0K | $127.0K |
| Unrealized loss on investments | $291.0K | -$103.0K |
| Reclassification of internal use software into prepaid expenses | $18.0K | $98.0K |
| Finance lease right-of use assets and finance lease liabilities recognized | $22.0K | |
| Amounts reclassified from deposit liabilities upon the vesting of early-exercised stock options previously subject to repurchase, net of proceeds received from early exercise of unvested stock options subject to repurchase and recorded as deposit liabilities | $37.0K | $59.0K |
| Unpaid offering costs included in accounts payable and accrued expenses | $25.0K | |
| property and equipment purchased in the current period included in accounts payable | -$120.0K |
No quarter-by-quarter statement was filed.
Leadership
Who has led Lexeo Therapeutics, Inc., and when. Pick a name to see everywhere that person has worked.
Chief executive
Chief financial officer
Chief operating officer
2025
- Chief executive officerRichard Nolan Townsend Nov 2, 2023 to now9
- Chief financial officerLouis Edward Tamayo Aug 27, 2025 to now10
- Chief financial officerKyle Rasbach Dec 27, 2024 to Jan 22, 202511
- Chief operating officerJose Manuel Otero Feb 6, 2026 to now12
Board members and other officers (16)
- Chief Medical OfficerNarinder Pal Bhalla Feb 5, 2026 to now13
- Chief Development OfficerTai Sandi See Feb 6, 2024 to now14
- Chief Technical OfficerJose Manuel Otero May 22, 2024 to now15
- Chief Scientific OfficerEric Adler Nov 2, 2023 to now16
- Chief Technical OfficerPaul McCormac Nov 2, 2023 to Nov 9, 202317
- Board memberLaura Sepp-Lorenzino Apr 30, 2026 to now18
- Board memberHauwermeiren Timothy Van Jul 8, 2024 to now19
- Board memberTolga Tanguler Nov 13, 2024 to now20
- Board memberBernard Davitian Nov 2, 2023 to Nov 2, 202321
- Board memberBrenda Cooperstone Nov 2, 2023 to now22
- Board memberMette Kirstine Agger Nov 2, 2023 to now23
- Board memberPaula H. Cholmondeley Nov 2, 2023 to now24
- Board memberReinaldo M. Diaz Nov 2, 2023 to now25
- Board memberRichard Nolan Townsend Nov 2, 2023 to now9
- Board memberSteven Altschuler Nov 2, 2023 to now26
- General counselJenny Robertson Nov 2, 2023 to now27
Timeline
- Nov 2, 2023New chief executive Richard Nolan Townsend becomes CEO9
Filings
359 filings to the SEC since October 2021: 3 annual reports, 10 quarterly reports, 38 major events, 121 insider forms, 62 large holders, 125 other. The latest 20:
- Oct 13, 2026SCHEDULE 13G EDGAR
- Sep 29, 20268-K EDGAR
- Sep 28, 20264 EDGAR
- Sep 28, 20264 EDGAR
- Sep 28, 20264 EDGAR
- Sep 28, 20264 EDGAR
- Sep 22, 20268-K EDGAR
- Aug 19, 20264 EDGAR
- Aug 19, 20264 EDGAR
- Aug 19, 20264 EDGAR
- Aug 18, 2026144 EDGAR
- Aug 18, 2026144 EDGAR
- Aug 18, 2026144 EDGAR
- Aug 14, 2026SCHEDULE 13G/A EDGAR
- Aug 14, 2026SCHEDULE 13G/A EDGAR
- Aug 14, 2026SCHEDULE 13G EDGAR
- Aug 13, 2026SCHEDULE 13G/A EDGAR
- Aug 12, 202610-Q EDGAR
- Aug 12, 20268-K EDGAR
- Aug 7, 2026SCHEDULE 13G EDGAR
The 359 filings since October 2021 can be filtered by form type and year here when JavaScript is on.
Every filing from the last five years, summarized. The full record is on SEC EDGAR.
Insider trades
50 open-market trades by officers, directors and large owners since October 2021: 4 buys and 46 sales. Grants, option exercises and gifts are left out.
| Date | Who | Trade | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Aug 18, 2026 | Tamayo Louis EdwardChief Financial Officer | Sale | 4,117 | $4.91 | $20.2K | Form 4 |
| Aug 18, 2026 | Otero Jose ManuelChief Operating Officer | Sale | 1,304 | $4.96 | $6.5K | Form 4 |
| Aug 18, 2026 | Townsend Richard NolanChief Executive Officer | Sale | 3,345 | $4.95 | $16.6K | Form 4 |
| Jul 1, 2026 | Bhalla Narinder PalChief Medical Officer | Sale | 22,306 | $4.42 | $98.6K | Form 4 |
| Jul 1, 2026 | Tamayo Louis EdwardChief Financial Officer | Sale | 4,641 | $4.49 | $20.8K | Form 4 |
| Jul 1, 2026 | Otero Jose ManuelChief Operating Officer | Sale | 4,666 | $4.48 | $20.9K | Form 4 |
| Jul 1, 2026 | Townsend Richard NolanChief Executive Officer | Sale | 25,947 | $4.48 | $116.2K | Form 4 |
| May 18, 2026 | Otero Jose ManuelChief Operating Officer | Sale | 1,302 | $5.07 | $6.6K | Form 4 |
| May 18, 2026 | Townsend Richard NolanChief Executive Officer | Sale | 3,342 | $5.06 | $16.9K | Form 4 |
| Apr 6, 2026 | Townsend Richard NolanChief Executive Officer | Sale | 55,000 | $5.69 | $312.9K | Form 4 |
| Feb 18, 2026 | Otero Jose ManuelChief Operating Officer | Sale | 3,016 | $6.40 | $19.3K | Form 4 |
| Feb 18, 2026 | Townsend Richard NolanChief Executive Officer | Sale | 10,173 | $6.38 | $64.9K | Form 4 |
| Nov 18, 2025 | Otero Jose ManuelChief Operating Officer | Sale | 721 | $9.27 | $6.7K | Form 4 |
| Nov 18, 2025 | See Tai SandiChief Development Officer | Sale | 386 | $9.27 | $3.6K | Form 4 |
| Nov 18, 2025 | Townsend Richard NolanChief Executive Officer | Sale | 1,127 | $9.27 | $10.4K | Form 4 |
| Nov 18, 2025 | Robertson JennyChief Legal Officer | Sale | 549 | $9.27 | $5.1K | Form 4 |
| Nov 18, 2025 | Adler EricChief Medical Officer | Sale | 615 | $9.27 | $5.7K | Form 4 |
| Oct 17, 2025 | Otero Jose ManuelChief Operating Officer | Sale | 2,115 | $8.95 | $18.9K | Form 4 |
| Oct 17, 2025 | See Tai SandiChief Development Officer | Sale | 3,888 | $8.95 | $34.8K | Form 4 |
| Oct 17, 2025 | Townsend Richard NolanChief Executive Officer | Sale | 13,133 | $8.95 | $117.5K | Form 4 |
All 50 trades can be filtered by person here when JavaScript is on.
From Forms 4 filed with the SEC.
Major holders
Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.
- JPMorgan ChaseSCHEDULE 13G, 1 filing Oct 13, 202628
- BALYASNY ASSET MANAGEMENT L.P.SCHEDULE 13G/A, 5 filings Aug 14, 2025 to Aug 14, 202629
- ORBIMED ADVISORS LLCSCHEDULE 13G, 1 filing Aug 14, 202630
- Paradigm Biocapital Advisors LPSCHEDULE 13G/A, 4 filings Nov 20, 2025 to Aug 14, 202631
- Affinity Asset Advisors, LLCSCHEDULE 13G/A, 3 filings Jun 4, 2025 to Aug 13, 202632
- State Street CorporationSCHEDULE 13G, 1 filing Aug 7, 202633
- MONTANOVA CAPITAL, LLCSCHEDULE 13G, 1 filing Apr 13, 202634
- VANGUARD GROUP INCSCHEDULE 13G/A, 2 filings Jan 30, 2026 to Mar 27, 202635
- CITADEL ADVISORS LLCSCHEDULE 13G/A, 4 filings Nov 17, 2023 to Feb 17, 202636
- Frazier Life Sciences Public Fund, L.P.SCHEDULE 13G/A, 3 filings Jun 4, 2025 to Feb 13, 202637
- BlackRockSCHEDULE 13G, 3 filings Feb 4, 2025 to Jan 21, 202638
- Janus Henderson Group Ltd.SCHEDULE 13G/A, 8 filings Feb 14, 2024 to Dec 8, 202539
- Longitude Capital Partners IV, LLCSCHEDULE 13G/A, 3 filings Feb 13, 2024 to Nov 14, 202540
- Vestal Point Capital, LPSCHEDULE 13G/A, 2 filings Aug 14, 2025 to Nov 14, 202541
- INTEGRATED CORE STRATEGIES (US) LLCSCHEDULE 13G/A, 3 filings Apr 28, 2025 to Nov 7, 202542
- RA CAPITAL MANAGEMENT, L.P.SCHEDULE 13G, 1 filing Oct 27, 202543
- D1 Capital Partners L.P.SCHEDULE 13G/A, 2 filings Feb 14, 2024 to May 15, 202544
- Adage Capital Management, L.P.SCHEDULE 13G/A, 3 filings Nov 12, 2024 to May 12, 202545
- EVENTIDE ASSET MANAGEMENT, LLCSCHEDULE 13G/A, 4 filings Dec 11, 2023 to Feb 14, 202546
- Omega Fund VI, L.P.SCHEDULE 13G/A, 2 filings Feb 14, 2024 to Feb 14, 202547
- Invest A/s LundbeckfondSC 13G/A, 2 filings Feb 14, 2024 to Nov 14, 202448
- Novo Holdings A/SSC 13G/A, 2 filings Nov 24, 2023 to Dec 15, 202349
Held by these funds
The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026, the top 25 of 100. Change is in shares since the quarter before.
| Fund | Shares | Value | Share of the fund | Change |
|---|---|---|---|---|
| Montanova Capital, LLC | 6,384,200 | $29.7M | 0.6% | +5,134,200 |
| Affinity Asset Advisors, LLC | 5,807,611 | $27.0M | 1.3% | +757,400 |
| BlackRock, Inc. | 5,739,455 | $26.7M | 0.0% | +628,584 |
| Ra Capital Management, L.P. | 5,000,000 | $23.3M | 0.2% | No change |
| Frazier Life Sciences Management, L.P. | 4,824,725 | $22.5M | 0.5% | +400,000 |
| State Street Corp | 4,354,757 | $20.3M | 0.0% | +786,515 |
| Vestal Point Capital, LP | 4,320,000 | $20.1M | 0.5% | −155,000 |
| Paradigm Biocapital Advisors LP | 4,175,382 | $19.4M | 0.4% | −2,008,752 |
| Jupiter Topco LLC | 3,954,691 | $18.4M | 0.0% | New |
| Orbimed Advisors LLC | 3,947,850 | $18.4M | 0.3% | +345,400 |
| Citadel Advisors LLC | 3,898,570 | $18.1M | 0.0% | +63,571 |
| Vanguard Capital Management LLC | 3,125,893 | $14.6M | 0.0% | +118,800 |
| Millennium Management LLC | 2,833,622 | $13.2M | 0.0% | +1,220,842 |
| Nantahala Capital Management, LLC | 2,600,000 | $12.1M | 0.4% | +1,400,000 |
| Woodline Partners LP | 2,500,532 | $11.6M | 0.0% | −250,000 |
| Balyasny Asset Management L.P. | 2,412,742 | $11.2M | 0.0% | +823,157 |
| Goldman Sachs Group Inc | 2,149,612 | $10.0M | 0.0% | +199,727 |
| 683 Capital Management, LLC | 1,875,000 | $8.7M | 0.8% | +675,000 |
| Geode Capital Management, LLC | 1,747,959 | $8.1M | 0.0% | +234,182 |
| ADAR1 Capital Management, LLC | 1,565,950 | $7.3M | 0.3% | +98,600 |
| Avoro Capital Advisors LLC | 1,489,189 | $6.9M | 0.1% | −385,811 |
| Qube Research & Technologies Ltd | 1,376,222 | $6.4M | 0.0% | +910,707 |
| Dimensional Fund Advisors LP | 1,287,185 | $6.0M | 0.0% | +183,601 |
| Spruce Street Capital LP | 928,593 | $4.3M | 0.8% | No change |
| Blackstone Inc. | 904,959 | $4.2M | 0.0% | No change |
13F reports cover disclosed long positions in U.S. stocks only.
Sources
The numbers on this page point here. Each one links to the record it came from.
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10
- 11
- 12
- 13
- 14
- 15
- 16SEC EDGAREric Adler, Chief Scientific Officer
- 17
- 18SEC EDGARLaura Sepp-Lorenzino, Board member
- 19
- 20SEC EDGARTolga Tanguler, Board member
- 21SEC EDGARBernard Davitian, Board member
- 22SEC EDGARBrenda Cooperstone, Board member
- 23SEC EDGARMette Kirstine Agger, Board member
- 24SEC EDGARPaula H. Cholmondeley, Board member
- 25SEC EDGARReinaldo M. Diaz, Board member
- 26SEC EDGARSteven Altschuler, Board member
- 27SEC EDGARJenny Robertson, General counsel
- 28
- 29
- 30
- 31
- 32
- 33
- 34
- 35
- 36
- 37
- 38
- 39
- 40
- 41
- 42
- 43
- 44
- 45
- 46
- 47
- 48
- 49